Professional Marketing briefs

Sanofi-Aventis settled a lawsuit accusing the company of underpaying 4,000 female reps in the US, and will pay $15.4 million as part of the settlement. Affected reps will see an increase in their base pay as a result of the settlement. Meanwhile a Novartis rep prevailed in her suit against the company, which she accused of slashing her territory and eliminating her position in retaliation for having taken maternity leave.

Valeant Pharmaceuticals entered into an agreement with Spear Pharmaceuticals for rights to commercialize Refissa, a prescription wrinkle and sun damage cream. Valeant will pay $12 million and the companies will share netprofit.

Arena Pharmaceuticals is looking for a commercial partner for its weight loss drug lorcaserin, pending approval, but will launch without if need be, the company told Reuters. The company is competing with Vivus Inc and Orexigen Therapeutics for first-to-market status.
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.